LLY
ELI LILLY
Stock XETRA – Stock Market Prices, News & Analysis
Entreprise pharmaceutique américaine spécialisée dans le développement de médicaments innovants pour le diabète, la neurodégénérescence et d'autres maladies.
ELI LILLY
LLY
Entreprise pharmaceutique américaine spécialisée dans le développement de médicaments innovants pour le diabète, la neurodégénérescence et d'autres maladies.
Price history of ELI LILLY
Price history of ELI LILLY
Performance & Momentum
Eli Lilly Soars on Obesity Drug Price Deal
Eli Lilly's shares hit new highs following an agreement with the White House to offer its obesity drugs at discounted prices. This move strengthens the company's position against rivals like Novo Nordisk, whose stock remains flat. Additionally, strong quarterly results and increased demand for its Mounjaro and Zepbound treatments bolster investor confidence. This positive momentum may lead to a sustained rise in share price, driven by trust in Eli Lilly's pipeline and commercial strategy.
Strategic Analysis
ELI LILLY • 2026
Eli Lilly positions itself as an innovative leader in the U.S. pharmaceutical sector, specializing in the development of cutting-edge treatments for diabetes and neurodegenerative diseases. Its business model is built on strong clinical research capabilities and biotechnology expertise, enabling it to address critical medical needs with differentiated medicines.
- Robust portfolio of innovative, high value-added medicines
- Recognized excellence in clinical research and biotechnology
- Sustained historical growth and therapeutic diversification
- High dependence on the success of clinical trials for new products
- Exposure to strict regulatory requirements that may delay product launches
The stock's momentum is very strong, driven by exceptional long-term performance and remarkable recent gains. This favorable trend reflects market confidence in Eli Lilly's innovation capabilities and commercial strength, enhancing its appeal to growth-oriented investors.
Similar stocks to ELI LILLY
Recent News
ELI LILLY
Eli Lilly Reports Promising Results for Omvoh in UC
6 months agoOn October 27, 2025, Eli Lilly announced positive data from a Phase 3b study of Omvoh (mirikizumab), a treatment targeting moderate to severe ulcerative colitis.
Eli Lilly to Invest $5B in New US Manufacturing Plant
7 months agoEli Lilly announced a $5 billion project to build an integrated plant in Virginia focused on pharmaceutical active ingredients and medicines. This development aims to boost domestic production and create 650 jobs within five years, reinforcing its commitment to the local supply chain. The stock remains stable, reflecting the market's cautious outlook on this long-term investment.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
